As per MRFR analysis, the Plaque Psoriasis Market Size was estimated at 6.75 (USD Billion) in 2023.The Plaque Psoriasis Market Industry is expected to grow from 6.98(USD Billion) in 2024 to 10.1 (USD Billion) by 2035. The Plaque Psoriasis Market CAGR (growth rate) is expected to be around 3.42% during the forecast period (2025 - 2035)
The Plaque Psoriasis Market is experiencing notable trends driven by rising awareness and advancements in treatment options. The increasing prevalence of plaque psoriasis globally, along with the push for more effective and individualized treatment plans, is significantly shaping the market. Biologics and targeted therapies are gaining traction due to their effectiveness in managing symptoms and improving patient quality of life.
This transition from traditional therapies to more advanced drug formulations illustrates the market's shift towards personalized medicine. Moreover, the expansion of research and development initiatives by pharmaceutical companies is vital for discovering new treatment pathways and innovative solutions.
Governments in various regions are emphasizing the need for comprehensive healthcare policies that support the accessibility of newer therapies for plaque psoriasis, thereby enhancing patient care. Opportunities to be explored include the growth potential in emerging markets where awareness and treatment resources are still developing. Collaboration between healthcare providers, patient advocacy groups, and pharmaceutical companies can foster better education and support for patients suffering from plaque psoriasis.
Recent trends also highlight the importance of telemedicine and digital health tools, which are being increasingly integrated into treatment regimens due to the convenience and accessibility they offer.
As technology advances, the incorporation of digital platforms for managing health and treatment adherence will likely become a significant aspect of care for plaque psoriasis patients globally.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Increasing Prevalence of Plaque Psoriasis
The Plaque Psoriasis Market Industry is expanding rapidly due to the rising incidence of plaque psoriasis. According to the Global Burden of Disease Study, an estimated 125 million individuals worldwide suffer from psoriasis, accounting for around 2-3% of the global population. A variety of variables, including genetic predisposition, environmental triggers, and lifestyle choices, contribute to the increasing incidence.
Established organizations such as the World Health Organization (WHO) have highlighted the critical need for better treatment alternatives, promoting market growth in the Plaque Psoriasis Market. The increase in patient numbers generates demand for novel therapies and goods, accelerating market growth.
This increased awareness and subsequent treatment must represent important future opportunities for players, propelling the market to an estimated Compound Annual Growth Rate (CAGR) of 3.42% from 2025 to 2035.
Advancements in Treatment Options
The Plaque Psoriasis Market Industry is propelled forward by advancements in treatment options, especially with the introduction of biological therapeutics and novel drugs. For instance, recent studies and advancements have shown that biologics, which target specific pathways in the immune response, can result in high rates of skin clearance for psoriasis patients.
The American Academy of Dermatology (AAD) notes that the number of biologics available to treat psoriasis has more than doubled in the past decade.
This surge in effective treatment options is crucial as it not only improves patient quality of life but also drives market growth. With pharmaceutical companies increasingly investing in Research and Development (R&D) for psoriasis treatments, the market anticipates further innovation and expansion in the coming years.
Growing Awareness and Education on Psoriasis
There is a notable increase in awareness and educational initiatives regarding psoriasis and its management, driving the Plaque Psoriasis Market Industry. Organizations such as the National Psoriasis Foundation (NPF) have been actively conducting campaigns and educational programs aimed at both patients and healthcare providers. This growing awareness is significant as it leads to earlier diagnosis and treatment, improving overall patient outcomes.
Research conducted by healthcare associations reveals that increased awareness can lead to a 20% increase in treatment adherence among patients, thereby positively impacting market demand. With more patients seeking treatment and support for their condition, the market is expected to see substantial growth, particularly as educational initiatives continue to gain momentum globally.
Increasing Investment in Healthcare Infrastructure
The Plaque Psoriasis Market Industry benefits from increasing investment in healthcare infrastructure across various regions, particularly in emerging economies. Governments worldwide, prompted by health crises and the need for better medical facilities, are ramping up investments in healthcare.
For example, the World Bank has reported a significant rise in global healthcare expenditures, with investments increasing by over 6% in many developing countries in the past five years.
This translates into improved access to healthcare services, including dermatological care for conditions like plaque psoriasis. As healthcare services become more accessible, it is expected that patient numbers will rise, subsequently fueling the demand for treatments in the Plaque Psoriasis Market.
The increased availability of healthcare resources will enhance the landscape for both established companies and new entrants within the market.
In the Plaque Psoriasis Market, the Treatment Type segment showcases a diverse array of therapeutic options, each contributing uniquely to the overall market dynamics. In 2024, the market for Topical Treatments was valued at 1.75 USD Billion, growing to 2.51 USD Billion by 2035, thus commanding a significant market share due to its widespread utilization as a first-line treatment approach for mild to moderate psoriasis cases.
This sub-segment remains essential as it provides localized management of symptoms with relatively lower systemic side effects, making it a preference for many patients and healthcare providers.
Systemic Treatments are expected to capture a market value of 2.4 USD Billion in 2024 and 3.34 USD Billion by 2035, signifying their critical role in managing moderate to severe plaque psoriasis, particularly given their effectiveness in addressing widespread skin involvement. This treatment type encompasses oral medications and injections that provide broader systemic effects, helping to control inflammation and plaques across the body, which is vital for patients dealing with more severe manifestations of the disease.
In contrast, Phototherapy, with a projected value of 1.05 USD Billion in 2024 and forecasted to grow to 1.57 USD Billion by 2035, serves as an important treatment category that utilizes UV light exposure to alleviate symptoms, highlighting its significance, particularly for patients who may not respond adequately to topical or systemic treatments alone.
Lastly, Biologic Therapies, valued at 1.78 USD Billion in 2024 and anticipated to reach 2.68 USD Billion by 2035, represent a rapidly advancing frontier in psoriasis treatment, reliant on targeting specific pathways involved in inflammation and immune response. This segment is essential as it demonstrates substantial efficacy in achieving long-term remission for severe plaque psoriasis, thus emerging as a preferred choice for patients seeking more advanced treatment options.
The market landscape indicates that each treatment type is strategically important, catering to varying degrees of severity and patient preferences, thereby contributing to the overall growth and diversification of the Plaque Psoriasis Market.
With the anticipated advancements in treatment modalities, there remain robust opportunities for market expansion across these diverse therapeutic avenues, driven by ongoing Research and Development and increasing awareness of psoriasis management. The evolving landscape presents both challenges and opportunities as the healthcare industry adapts to the needs of patients and integrates newer, effective treatment solutions into routine clinical practice.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Plaque Psoriasis Market is witnessing significant growth, driven by the increasing prevalence of plaque psoriasis and the rising demand for effective treatment options through various routes of administration. Expected to reach a valuation of 6.98 billion USD by 2024, the market reflects a steady growth trajectory.
Within this framework, the Route of Administration segment plays a crucial role, categorized into Topical, Oral, Injectable, and Intravenous administration methods. Topical treatments are commonly utilized due to their direct application on affected areas, ensuring targeted delivery and minimizing systemic side effects.
Oral administration is gaining traction for its convenience and ease of use, appealing to patients looking for non-invasive options. Injectable methods account for a significant portion of treatment regimens because of their rapid efficacy and effectiveness for moderate to severe cases, while Intravenous options are typically reserved for severe conditions requiring immediate intervention.
The diversity of these routes not only enhances patient adherence but also caters to varying disease severity levels, thereby sustaining the Plaque Psoriasis Market growth.
Recent trends highlight a shift towards biotechnological advancements and the development of novel formulations, presenting opportunities for stakeholders to innovate and capture market share, while the overall Plaque Psoriasis Market statistics underscore the importance of targeted and effective treatment strategies moving forward.
The Disease Severity segment of the Plaque Psoriasis Market exhibits a diversified structure, encompassing categories such as Mild, Moderate, and Severe conditions. In the year 2024, the overall Plaque Psoriasis Market is projected to reach a value of 6.98 USD Billion, highlighting the relevance of addressing varying severity levels.
Market growth in this segment is significantly influenced by factors such as increasing diagnosis rates, growing awareness of plaque psoriasis, and advancements in treatment options. Among these categories, Moderate and Severe cases often warrant more comprehensive medical interventions, thus representing a critical area for pharmaceutical development.
Severe plaque psoriasis not only imposes a greater burden on individuals but also significantly affects quality of life, necessitating more advanced therapies. Growing innovations in treatment methodologies, along with an increasing number of patients seeking effective management, further drive the demand and research within this segment.
As healthcare systems globally prioritize effective management strategies, exploring the dynamics within the Disease Severity segment will be essential for future Plaque Psoriasis Market statistics and industry growth.
The Plaque Psoriasis Market emphasizes patient demographics, which include Adults, Children, and the Elderly, to understand the complexities of this condition. By 2024, the overall market is expected to be valued at 6.98 billion USD, showcasing a steady growth trajectory influenced by various factors.
Adults form a significant part of the patient demographics due to the prevalence of lifestyle-related triggers, while Children also represent a growing segment, as early-onset psoriasis can lead to long-term health complications if not managed properly.
The Elderly population experiences unique challenges associated with this condition, such as age-related skin sensitivity and comorbidities, making tailored treatments essential. The increasing awareness about skin health and the introduction of newer biologic therapies drive the market growth, alongside rising healthcare expenditure worldwide.
However, challenges such as high treatment costs and access to care in various regions pose barriers to effective management. The Plaque Psoriasis Market data indicates opportunities to innovate in treatment modalities, particularly for vulnerable subgroups, ensuring a more holistic approach towards managing this chronic skin disorder.
The Plaque Psoriasis Market is significantly diversified across various regions, with North America emerging as a leading player, valued at 2.8 USD Billion in 2024 and expected to reach 4.1 USD Billion by 2035. This dominance is attributed to advanced healthcare infrastructure and the growing prevalence of psoriasis in the region.
Europe follows closely, with a valuation of 2.3 USD Billion in 2024 and an estimated growth to 3.3 USD Billion by 2035, supported by increasing investments in innovative treatments. In South America, the market is projected to be valued at 0.5 USD Billion in 2024 and 0.8 USD Billion in 2035, indicating steady growth as awareness and diagnosis improve.
The Asia Pacific region shows promising expansion, anticipated to rise from 1.3 USD Billion in 2024 to 1.9 USD Billion by 2035, driven by a large population base and evolving healthcare facilities. Meanwhile, the Middle East and Africa currently hold a smaller market share, valued at 0.2 USD Billion in 2024, with an expected increase to 0.3 USD Billion by 2035, reflecting challenges in healthcare access that need to be addressed. Such market growth is primarily fueled by the increasing incidence of plaque psoriasis and the demand for effective treatment options across all regions, making the Plaque Psoriasis Market a crucial area for investment and development.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Plaque Psoriasis Market Key Players and Competitive Insights
The Plaque Psoriasis Market has become increasingly competitive as pharmaceutical companies strive to develop effective treatments for this chronic autoimmune condition. The rising prevalence of plaque psoriasis worldwide has triggered heightened research and development activities, resulting in a diverse range of therapeutic options, including biologics, small molecules, and phototherapy. Key players are focusing on innovations that enhance efficacy, reduce side effects, and improve patient adherence to treatment regimens.
As awareness around plaque psoriasis grows, so does the demand for advanced medication, creating immense opportunities for companies that can deliver effective solutions. The competitive landscape is characterized by collaborations, strategic alliances, and advancements in technology, positioning companies to leverage their strengths in understanding patient needs and market dynamics.
Novartis has established a strong presence in the Plaque Psoriasis Market, primarily due to its commitment to innovative research and the development of high-quality therapeutic options. The company's portfolio includes several products designed specifically for managing plaque psoriasis, and its robust pipeline indicates a focus on expanding treatment alternatives. Novartis has excelled in clinical trials, demonstrating a high efficacy rate in their offerings, which has significantly enhanced its reputation among healthcare providers and patients alike.
The strength of Novartis lies in its extensive global reach and strong relationships with healthcare professionals, allowing for effective product distribution and increased patient access to new therapies. The company's continuous investment in research and development ensures that it remains at the forefront of innovation in treating plaque psoriasis.
Merck has also made notable strides in the Plaque Psoriasis Market with a diverse portfolio of treatments aimed at addressing the needs of patients with this condition. The company's key products offer therapeutic benefits for patients experiencing moderate to severe plaque psoriasis, leveraging both innovative biotechnology and established treatment protocols. Merck's market presence is reinforced through strategic mergers and acquisitions that have expanded its capabilities and product offerings in the dermatology field.
By focusing on patient-centric solutions and maintaining a strong commitment to research, Merck continuously enhances its competitive edge. The company has also prioritized collaborations with research institutions and healthcare providers to further investigate the underlying mechanisms of psoriasis, ultimately leading to better therapeutic outcomes and improved patient care.
Key Companies in the Plaque Psoriasis Market Include
Plaque Psoriasis Market Industry Developments
Recent developments in the Plaque Psoriasis Market highlight ongoing advancements and strategic movements among key players. Notably, Novartis continues to innovate with new data supporting its treatment efficacy, while AbbVie maintains a strong market presence through its diversified portfolio.
In terms of mergers and acquisitions, there were no significant announcements implicating the major companies like Merck, Dermira, Celgene, Gilead Sciences, Takeda, Amgen, AstraZeneca, UCB, Eli Lilly, Incyte, Sanofi, Johnson & Johnson, Bristol-Myers Squibb, and AbbVie in the past few months. Growth in the market valuation of these companies is driven by increasing R&D investments and emerging therapies addressing unmet medical needs, which bolster market dynamics.
For instance, in August 2022, Gilead Sciences acquired a promising therapeutic asset that could enhance its treatment offerings. The overall market is expected to expand significantly as awareness of plaque psoriasis and therapeutic advancements grows, fueled by collaborative efforts in Research and Development among companies striving to deliver innovative solutions to patients. The Plaque Psoriasis Market remains dynamic, with industry stakeholders focusing on enhancing patient outcomes and market reach.
| Report Attribute/Metric | Details |
| Market Size 2023 | 6.75(USD Billion) |
| Market Size 2024 | 6.98(USD Billion) |
| Market Size 2035 | 10.1(USD Billion) |
| Compound Annual Growth Rate (CAGR) | 3.42% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Novartis, Merck, Celgene, Amgen, AstraZeneca, UCB, Eli Lilly, Sanofi, Johnson & Johnson, BristolMyers Squibb, AbbVie |
| Segments Covered | Treatment Type, Route of Administration, Disease Severity, Patient Demographics, Regional |
| Key Market Opportunities | Increasing awareness and diagnosis, Rising biologics adoption, Growth in telemedicine solutions, Expanding pipeline for innovative treatments, Emerging markets accessibility improvements |
| Key Market Dynamics | rising prevalence of psoriasis, increasing treatment options, growing awareness of skin conditions, advancements in biologic therapies, high unmet medical needs |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Plaque Psoriasis Market was valued at 6.98 USD Billion in 2024.
By 2035, the Plaque Psoriasis Market is projected to reach a value of 10.1 USD Billion.
The expected CAGR for the Plaque Psoriasis Market is 3.42% from 2025 to 2035.
By 2035, North America is anticipated to hold the largest market share, valued at 4.1 USD Billion.
The Biologic Therapies segment is projected to be valued at 2.68 USD Billion in 2035.
Key players in the Plaque Psoriasis Market include Novartis, Merck, and AbbVie, among others.
The Systemic Treatments segment was valued at 2.4 USD Billion in 2024.
The Asia Pacific region is forecasted to reach a market size of 1.9 USD Billion by 2035.
The Topical Treatments segment is expected to be valued at 2.51 USD Billion in 2035.
Emerging trends include advancements in treatment options, increased awareness, and a growing patient population.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
